Globe Life (GL) reported $1.52 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.1%. EPS of $4.81 for the same period compares to $3.49 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.52 billion, representing a surprise of -0.12%. The company delivered an EPS surprise of +5.95%, with the consensus EPS estimate being $4.54.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Globe Life performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenue- Total premium: $1.23 billion versus the five-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +5%.
- Revenue- Net investment income: $286.01 million compared to the $286.47 million average estimate based on five analysts. The reported number represents a change of +0.4% year over year.
- Revenue- Life premium: $844.48 million compared to the $852 million average estimate based on four analysts. The reported number represents a change of +3.2% year over year.
- Revenue- Health premium: $386.52 million versus the four-analyst average estimate of $382.7 million. The reported number represents a year-over-year change of +9.2%.
- Life Underwriting Margin- Other: $36.45 million versus the three-analyst average estimate of $34.24 million. The reported number represents a year-over-year change of +10.6%.
- Life Underwriting Margin- Liberty National: $70.29 million compared to the $49.32 million average estimate based on three analysts. The reported number represents a change of +57.2% year over year.
- Life Underwriting Margin- Direct to Consumer: $113.74 million compared to the $107.06 million average estimate based on three analysts. The reported number represents a change of +28.9% year over year.
- Life Underwriting Margin- American Income: $261.12 million versus $261.23 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18% change.
- Revenue- Other income (loss): $0.96 million versus $0.07 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2173.8% change.
- Revenue- Health premium- Direct to Consumer: $19.19 million versus $19.19 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
- Revenue- Health premium- Family Heritage: $118.64 million versus $117.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10% change.
- Revenue- Health premium- American Income: $31.69 million compared to the $31.89 million average estimate based on three analysts. The reported number represents a change of +1.3% year over year.
View all Key Company Metrics for Globe Life here>>>
Shares of Globe Life have returned -7.2% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>Globe Life Inc. (GL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
